9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 101–200 of 1,000
Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes
Preiser, J., Provenzano, B. C., Wasineeart, M., Halenarova, K. W., & Cnop, M. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003237 · Cited by 69
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns
(2025) · The American Journal of Managed Care · doi:10.37765/ajmc.2025.89778 · Cited by 65
Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Abildlund, M. T., Pratley, R., Vilsbøll, T., & Husain, M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14990 · Cited by 55
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 62
Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Barchetta, I., Cimini, F. A., Dule, S., & Cavallo, M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10092306 · Cited by 55
Zhang, H., Wang, Y., Chen, C., Lu, Y., & Wang, N. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001513 · Cited by 62
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F., Vasques-Nóvoa, F., Leite-Moreira, A., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 54
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
“They are not only recommended as the primary therapy in certain situations but also as an early supplement to metformin [57,95].”
BackgroundPrevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Limonte, C. P., Hall, Y. N., Trikudanathan, S., Tuttle, K. R., Hirsch, I. B., de Boer, I. H., & Zelnick, L. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108204 · Cited by 58
Acute Kidney Injury Associated With Semaglutide
Leehey, D. J., Rahman, M. A., Borys, E., Picken, M. M., & Clise, C. E. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.10.008 · Cited by 51
Orandi, B. J., Chen, Y., Li, Y., Metoyer, G. T., Lentine, K. L., Weintraub, M. D., Bae, S., Ali, N. M., Lonze, B. E., Ren‐Fielding, C. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00371-1 · Cited by 64
Hamid, A., Vaduganathan, M., Oshunbade, A. A., Ayyalasomayajula, K. K., Kalogeropoulos, A. P., Lien, L. F., Shafi, T., Hall, M. E., & Butler, J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000864 · Cited by 57
Changes in the use of glucose‐lowering drugs: A Danish nationwide study
Pottegård, A., Andersen, J. H., Søndergaard, J., Thomsen, R. W., & Vilsbøll, T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14947 · Cited by 54
Lingvay, I., Mosenzon, O., Brown, K., Cui, X., O’Neill, C., Fernández Landó, L., & Patel, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01797-5 · Cited by 55
Su, Y., Hung, J., Chang, K., Sun, C., Huang, Y.-H., Lee, C., Hung, M., Lai, C., Shao, S., & Lai, E. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.32584 · Cited by 60
German, C. A., Baum, S. J., Ferdinand, K. C., Gulati, M., Polonsky, T. S., Toth, P. P., & Shapiro, M. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100432 · Cited by 60
Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis
Zhang, J., Muise, E. S., Han, S., Kutchukian, P. S., Costet, P., Zhu, Y., Kan, Y., Zhou, H., Shah, V., Huang, Y., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100056 · Cited by 59
Cusi, K. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52
Han, T., Ma, S., Sun, C., Zhang, H., Qu, G., Chen, Y., Cheng, C., Chen, E. L., Ahmed, M. A., Kim, K. Y., et al. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.08.002 · Cited by 59
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 50
Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 50
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 60
Liu, B. D. X., Udemba, S. C., Liang, K., Tarabichi, Y., Hill, H., Fass, R., & Song, G. (2023) · Gut · doi:10.1136/gutjnl-2023-329651 · Cited by 61
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 68
Pinto, S., Hosseini, M., Buckley, S. T., Yin, W., Garousi, J., Gräslund, T., van IJzendoorn, S., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.015 · Cited by 53
Loi, H., Boal, F., Tronchère, H., Cinato, M., Крамар, С., Oleshchuk, O., Korda, M. M., & Kunduzova, O. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00154 · Cited by 53
RetractedImpairment of Mitochondrial Respiration in Metabolic Diseases: An Overview
Avram, V. F., Merce, A. P., Hâncu, I. M., Bătrîn, A. D., Kennedy, G., Rosca, M. G., & Muntean, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168852 · Cited by 54
Lauffenburger, J. C., Ghazinouri, R., Jan, S., Makanji, S., Ferro, C. A., Lewey, J., Wittbrodt, E., Lee, J., Haff, N., Fontanet, C. P., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214754 · Cited by 50
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review
Mohottige, D., Manley, H. J., & Hall, R. K. (2021) · Kidney360 · doi:10.34067/kid.0001942021 · Cited by 52
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Bendotti, G., Montefusco, L. B., Pastore, I., Lazzaroni, E., Lunati, M. E., & Fiorina, P. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02162-9 · Cited by 53
Jain, V., Minhas, A. M. K., Ariss, R. W., Nazir, S., Khan, S. U., Khan, M. S., Rifai, M. A., Michos, E. D., Mehta, A., Qamar, A., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.03.002 · Cited by 54
Retinal microcirculation: A window into systemic circulation and metabolic disease
Yuan, Y., Dong, M., Wen, S., Yuan, X., & Zhou, L. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109885 · Cited by 54
Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J. (2019) · Diabetic Medicine · doi:10.1111/dme.13898 · Cited by 43
The Role of Beta Cell Recovery in Type 2 Diabetes Remission
Suleiman, M., Marselli, L., Cnop, M., Eizirik, D. L., Luca, C. D., Femia, F. R., Tesi, M., Guerra, S. D., & Marchetti, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137435 · Cited by 49
Baviera, M., Foresta, A., Colacioppo, P., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Genovese, S., Caruso, I., & Giorgino, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01572-y · Cited by 53
Post-transplant diabetes mellitus following heart transplantation
Newman, J. D., Schlendorf, K. H., Cox, Z. L., ZALAWADIYA, S. K., Powers, A. C., Niswender, K. D., Shah, R. V., & Lindenfeld, J. M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.011 · Cited by 49
Yang, C.-T., Yang, C.-Y., Ou, H.-T., & Kuo, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01053-0 · Cited by 48
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 49
Rocha, S., Lucas, M., Ribeiro, D., Corvo, M. L., Fernandes, E. G. R., & Freitas, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105604 · Cited by 50
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
“According to the ADA 2022, 7 for patients with type 2 diabetes who also have established or a high risk of atherosclerotic cardiovascular disease, established kidney disease, or heart failure, an SGLT-2 inhibitor or GLP-1 receptor agonist with demonstrated cardio-vascular benefi t with or without…”
BackgroundCohen, R. V., Pereira, T. V., Aboud, C. M., Zanata Petry, T. B., Lopes Correa, J. L., Schiavon, C. A., Pompílio, C. E., Quirino Pechy, F. N., Calmon da Costa Silva, A. C., Cunha da Silveira, L. P., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101725 · Cited by 41
Insulin resistance in Alzheimer’s disease: The genetics and metabolomics links
Amin, A. M., Mostafa, H. M. A., & Khojah, H. M. J. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.12.016 · Cited by 52
Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review
Gavin, J. R., Abaniel, R. M., & Virdi, N. S. (2023) · Diabetes Spectrum · doi:10.2337/ds22-0084 · Cited by 49
Kunutsor, S. K., Zaccardi, F., Balasubramanian, V. G., Gillies, C., Aroda, V. R., Seidu, S., Davies, M. J., & Khunti, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15500 · Cited by 48
Gomez-Peralta, F., Escalada San Martín, F. J., Menéndez Torre, E., Mata Cases, M., Ferrer García, J. C., Ezkurra Loiola, P., Ávila Lachica, L., Fornos Pérez, J. A., Artola Menéndez, S., Álvarez-Guisasola, F., et al. (2018) · Endocrinología, Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 39
Lemke, A. I., Brokmeier, H. M., Leung, S. B., Mara, K. C., Mour, G. K., Wadei, H. M., Hill, J. M., Stegall, M. D., Kudva, Y. C., Shah, P., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14718 · Cited by 44
Ullah, A., & Shen, B. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118065 · Cited by 48
Carbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 46
Type 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity
Marrano, N., Biondi, G., Borrelli, A., Rella, M., Zambetta, T., Gioia, L. D., Caporusso, M., Logroscino, G., Perrini, S., Giorgino, F., et al. (2023) · Biomolecules · doi:10.3390/biom13010183 · Cited by 51
Santos, L. B., Mizubuti, G. B., da Silva, L. M., Silveira, S. Q., Nersessian, R. S. F., Abib, A. D. C. V., Bellicieri, F. N., Lima, H. D. O., Ho, A. M.-H., dos Anjos, G. S., et al. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111668 · Cited by 43
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108332 · Cited by 43
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J. R., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 45
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“Apart from its glucose-lowering effects, in large clinical trials, pioglitazone seems to retard the atherosclerotic process and reduce the risk of cardiovascular events [195–197].”
Estándares SEA 2022 para el control global del riesgo cardiovascular
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.11.003 · Cited by 70
Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., Monda, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020322 · Cited by 44
Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions
Mesquita, L. D. A., Wayerbacher, L. F., Schwartsmann, G., & Gerchman, F. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000647 · Cited by 52
“Current guidelines recommend GLP-1RAs as initial therapy or in combination with metformin for patients with type 2 diabetes and high cardiovascular risk (71), and two GLP-1RAs, liraglutide and semaglutide, are approved for the treatment of obesity after results from large clinical trials (90,91).”
BackgroundInfluentialQi, M., Santos, H., da Silva, P. P., McGuinness, D. L., & Bennett, K. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290692 · Cited by 51
Perioperative management of patients on glucagon-like peptide-1 receptor agonists
Mizubuti, G. B., Ho, A. M. ‐., da Silva, L. M., & Phelan, R. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001348 · Cited by 44
Khunti, K., Jabbour, S. A., Cos, X., Mudaliar, S. R. D., Mende, C. W., Bonaca, M. P., & Fioretto, P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14684 · Cited by 45
Glucose metabolism in Cushing's syndrome
Sharma, A. R., & Vella, A. V. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000537 · Cited by 44
Bitirim, C. V., Aksoy, Z. B., Aydos, D., Genc, K., Demirsoy, Ş., Akçalı, K. C., & Turan, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-09627-6 · Cited by 42
Alicic, R. Z., & Nicholas, S. B. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.05.003 · Cited by 48
Frias, J. P., Choi, J., Rosenstock, J., Popescu, L., Niemoeller, E., Muehlen-Bartmer, I., & Baek, S. (2022) · Diabetes Care · doi:10.2337/dc21-2656 · Cited by 38
Yang, S., Liu, Y., Zhang, S., Wu, F., Liu, D., Wu, Q., Zheng, H., Fan, P., & Su, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1145587 · Cited by 42
Saengboonmee, C., Seubwai, W., Lert-itthiporn, W., Sanlung, T., & Wongkham, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.008 · Cited by 48
Aroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
Lim, C.-E., Pasternak, B., Eliasson, B., Danaei, G., & Ueda, P. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac315 · Cited by 45
SGLT2 Inhibitors in Kidney Diseases—A Narrative Review
Gajewska, A., Wasiak, J., Sapeda, N., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094959 · Cited by 48
“Currently, these drugs are allowed as first-line treatment for monotherapy in type 2 diabetes [53].”
BackgroundShao, S., Lin, Y.-H., Chang, K., Chan, Y., Hung, M., Yang, Y. K., & Lai, E. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000742 · Cited by 40
Shin, J.-I., Sang, Y., Chang, A. R., Dunning, S. C., Coresh, J., Inker, L. A., Selvin, E., Ballew, S. H., & Grams, M. E. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019101119 · Cited by 38
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
McCormick, N., Yokose, C., Wei, J., Lu, N., Wexler, D. J., Aviña-Zubieta, J. A., Vera, M. A. D., Zhang, Y., & Choi, H. K. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0724 · Cited by 39
Li, X., Jiang, X., Jiang, M., Wang, Z., Zhao, T., Cao, S.-M., & Li, Q. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02184-y · Cited by 41
“Many studies, including the ADA consensus [38], have shown that various GLP-1RAs, such as liraglutide and semaglutide, can delay the progression of DKD [19].”
Cagrilintide plus semaglutide for obesity management
Becerril, S., & Frühbeck, G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00944-2 · Cited by 38
Gomes, A., Coelho, P. P. O. L., Soares, R. A., & Costa, R. (2021) · Cell and Tissue Research · doi:10.1007/s00441-021-03461-4 · Cited by 39
Yang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.003 · Cited by 37
Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.02.001 · Cited by 43
Boonpattharatthiti, K., Saensook, T., Neelapaijit, N., Sakunrag, I., Krass, I., & Dhippayom, T. (2023) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2023.11.009 · Cited by 41
Bagepally, B. S., Gurav, Y. K., Anothaisintawee, T., Youngkong, S., Chaikledkaew, U., & Thakkinstian, A. (2019) · Value in Health · doi:10.1016/j.jval.2019.09.2750 · Cited by 37
Biosynthetic Human Insulin and Insulin Analogs
Rodbard, H. W., & Rodbard, D. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001089 · Cited by 46
Yang, A., Wu, H., Lau, E. S. H., Zhang, X., Shi, M., Fan, B., Ronald, C. W., Kong, A. P. S., Luk, A. O. Y., Chan, J. C. N., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100509 · Cited by 44
Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez‐Valderas, E., Allen, S. E., Ranta, K., Torcello‐Gómez, A., & Thieu, V. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14943 · Cited by 36
Hui, E. K., Mukadam, N., Kohl, G., & Livingston, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319054 · Cited by 39
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
Abrahami, D., Tesfaye, H., Yin, H., Vine, S. M., Hicks, B. M., Yu, O. H. Y., Campeau, L., Platt, R. W., Schneeweiß, S., Patorno, E., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1174 · Cited by 37
Association of sulfonylureas with the risk of dementia: A population‐based cohort study
Wu, C., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18397 · Cited by 38
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
“Per os administration once daily, and the relatively low rates of hypoglycemic episodes have increased DPP-4Is use for T2D patients with unstable glucose levels [10, 90].”
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
Cardiovascular Impact of Race and Ethnicity in Patients With Diabetes and Obesity
Joseph, J. J., Ortiz, R., Acharya, T., Golden, S. H., López, L., & DEEDWANIA, P. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.020 · Cited by 38
New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment
Haddad, D., Dsouza, V. S., Al‐Mulla, F., & Madhoun, A. S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010571 · Cited by 37
Yoo, H., Choo, E., & Lee, S. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00605-5 · Cited by 38
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101390 · Cited by 36
Qin, C., Díaz-Gallo, L.-M., Tang, B., Wang, Y., Nguyen, T.-D., Harder, A., Lu, Y., Padyukov, L., Askling, J., & Hägg, S. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-01000-9 · Cited by 38
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
Yaseen, A., & Lahiri, S. W. (2023) · Clinical Diabetes · doi:10.2337/cd22-0100 · Cited by 38
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
Polyunsaturated fatty acids and metabolic health: novel insights
Djuricic, I. D., & Calder, P. C. (2022) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000865 · Cited by 44
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.